Front Cover: Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies (ChemMedChem 21/2018)

The Front Cover shows vilaprisan, a highly selective progesterone receptor modulator (SPRM), bound to the progesterone receptor (PR). Gynecologic diseases such as uterine fibroids and endometriosis depend on progesterone receptor function. Women affected by these diseases may suffer from heavy menstrual bleeding, pelvic pain, and/or infertility. Based on its high potency, high selectivity for the PR, and favorable pharmacokinetic properties, vilaprisan has the potential to offer a medical solution addressing the high unmet need in these indications. More information can be found in the Full Paper by Wolfgang Schwede et al. on page 2271 in Issue 21, 2018 (DOI: 10.1002/cmdc.201800487).